Technical Analysis for CYBN - Cybin Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Multiple of Ten Bearish | Other | 0.00% | |
| NR7 | Range Contraction | -0.40% | |
| Multiple of Ten Bullish | Other | -0.40% | |
| Inside Day | Range Contraction | -0.40% | |
| Fell Below 20 DMA | Bearish | 0.81% | |
| MACD Bearish Signal Line Cross | Bearish | 0.81% | |
| Multiple of Ten Bearish | Other | 0.81% | |
| Wide Bands | Range Expansion | 0.81% | |
| Wide Bands | Range Expansion | -4.86% | |
| Wide Bands | Range Expansion | -6.37% |
| Alert | Time |
|---|---|
| Possible NR7 | about 21 hours ago |
| Rose Above Previous Day's High | about 24 hours ago |
| Up 1% | about 24 hours ago |
| Possible NR7 | 2 days ago |
| Possible Inside Day | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 06/26/2024
Cybin Inc. Description
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Drugs Major Depressive Disorder Neurochemistry Psychedelic Drug
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.3136 |
| 52 Week Low | 6.5 |
| Average Volume | 198,887 |
| 200-Day Moving Average | 11.99 |
| 50-Day Moving Average | 9.45 |
| 20-Day Moving Average | 10.20 |
| 10-Day Moving Average | 10.55 |
| Average True Range | 0.63 |
| RSI (14) | 50.74 |
| ADX | 37.38 |
| +DI | 24.13 |
| -DI | 18.14 |
| Chandelier Exit (Long, 3 ATRs) | 9.78 |
| Chandelier Exit (Short, 3 ATRs) | 10.48 |
| Upper Bollinger Bands | 11.59 |
| Lower Bollinger Band | 8.81 |
| Percent B (%b) | 0.42 |
| BandWidth | 27.30 |
| MACD Line | 0.23 |
| MACD Signal Line | 0.34 |
| MACD Histogram | -0.104 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.59 | ||||
| Resistance 3 (R3) | 10.59 | 10.40 | 10.49 | ||
| Resistance 2 (R2) | 10.40 | 10.24 | 10.40 | 10.46 | |
| Resistance 1 (R1) | 10.19 | 10.15 | 10.19 | 10.19 | 10.42 |
| Pivot Point | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Support 1 (S1) | 9.79 | 9.84 | 9.79 | 9.79 | 9.56 |
| Support 2 (S2) | 9.60 | 9.75 | 9.60 | 9.52 | |
| Support 3 (S3) | 9.39 | 9.60 | 9.49 | ||
| Support 4 (S4) | 9.39 |
